Adj. EBITDA was USD9.0m, broadly in line with our estimate and consensus. Human Health Ingredients (HHI) beat expectations on higher volumes sold and a higher gross margin, and Emerging Businesses (EB) reported lower losses than expected from significantly reduced marketing spending. Encouragingly, management noted a limited impact of tariffs on HHI financials, where c20% of krill oil sales are from the US to China. We have only made minor adjustments to our estimates following the results, and ...
We expect Q1 adj. EBITDA of USD9.4m, USD4.3m (-31%) below consensus of USD13.6m. With sales of USD51m (10% below consensus of USD57m), our estimates correspond to an adj. EBITDA margin of 18.2% versus consensus of 23.9%. The results are due at 07:00 CET on 30 April. As the strategy of maximising value through transactions for its remaining assets is the main potential share price catalyst in our view, the quarterly reported numbers would be of less relevance. We reiterate our BUY, but ha...
Q4 adj. EBITDA of USD7.4m was above our USD2.1m estimate and broadly in line with consensus, albeit driven by positive adjustments. Reported EBITDA was USD3.4m, versus our USD2.1m estimate and consensus of USD6.6m. Management’s outlook comments were in line with our estimates for 2025, and we have made only minor positive EPS revisions in light of the report. As we expect a 53% increase in adj. EBITDA YOY in 2025, we highlight that delivery is needed from Q1. We reiterate our BUY and have raised...
We expect Q4 adj. EBITDA of USD2.1m, USD6.9m below consensus of USD9.0m. With sales of USD54m, our estimates correspond to a margin of 3.9% versus consensus of 16.9%. The results are due at 07:00 CET on 12 February. As the strategy of maximising value through transactions for its remaining assets is the main potential share price catalyst in our view, the quarterly reported numbers are of less relevance. However, more transactions are likely needed to crystallise underlying value. We reiterate o...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.